---
title: "Earnings Flash (NVCR) Novocure Limited Reports Q3 Revenue $167.20M, vs. FactSet Est of $158.9M"
description: "Earnings Flash (NVCR) Novocure Limited Reports Q3 Revenue $167.20M, vs. FactSet Est of $158.9M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263507250.md"
published_at: "2025-10-30T11:37:24.000Z"
---

# Earnings Flash (NVCR) Novocure Limited Reports Q3 Revenue $167.20M, vs. FactSet Est of $158.9M

### Related Stocks

- [NVCR.US - Novocure](https://longbridge.com/en/quote/NVCR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| FDA Approves First-Of-Its-Kind Device To Treat Pancreatic Cancer | Novocure Ltd :FDA APPROVES FIRST-OF-ITS-KIND DEVICE TO TREAT PANCREATIC CANCERFDA: APPROVED NOVOCURE'S OPTUNE PAX, A FIR | [Link](https://longbridge.com/en/news/275768787.md) |
| NovoCure Shares Surge 34% Over FDA Approval For Optune Pax | NovoCure Limited (NVCR) shares surged 34% following FDA approval of Optune Pax for adult patients with locally advanced  | [Link](https://longbridge.com/en/news/275778716.md) |
| 11:17 ETNew Treatment Modalities Are Reaching Cancers That Resisted Everything Else | Oncolytics Biotech Inc. has received Fast Track Designation from the FDA for its cancer treatment pelareorep, showing si | [Link](https://longbridge.com/en/news/276146801.md) |
| Novocure Names Frank Leonard as Chief Executive Officer | Novocure Ltd. has appointed Frank Leonard as its new Chief Executive Officer, succeeding his role as President. This ann | [Link](https://longbridge.com/en/news/272298426.md) |
| U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer \| NVCR Stock News | The U.S. FDA has approved Novocure’s Optune Pax® for treating locally advanced pancreatic cancer, marking the first new  | [Link](https://longbridge.com/en/news/275670850.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.